Stock Analysis, Dividends, Split History

DAIO / Data I/O Corp. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price5.28
Volume19,400.00
Market Cap ($M)52.67
Enterprise Value ($M)35.86
Book Value ($M)22.67
Book Value / Share2.69
Price / Book1.98
NCAV / Sharen/a
Price / NCAVn/a
Share Statistics
Common Stock Shares Outstanding 8,276,813
Preferred Stock Shares Outstanding 0
Common Shares Outstanding 8,293,267
Scoring Models
Piotroski F-Score6.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)0.25
Return on Assets (ROA)0.24
Return on Equity (ROE)0.34
Balance Sheet (mrq) ($M)
Assets29.77
Liabilities7.10
Quick Ratio3.40
Current Ratio4.05
Income Statement (mra) ($M)
Sales Revenue Goods Net0.00
Revenues34,051,000.00
Operating Income5.05
Net Income5.45
Earnings Per Share Diluted0.65
Earnings Per Share Basic0.67
Cash Flow Statement (mra) ($M)
Cash From Operations9.13
Cash from Investing-1.79
Cash from Financing-1.79
Identifiers and Descriptors
CUSIP237690102
Central Index Key (CIK)351998

Split History

Stock splits are used by Data I/O Corp. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

16h - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

16h - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

18h - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Related News Stories

Data I/O Is Priced For A Crash That Isn't In Sight

2018-07-30 seekingalpha
It looks like investors took their cue from a single disappointing data point, backlog and concluded the cyclical downturn is getting worse.

Data I/O Corporation (DAIO) CEO Anthony Ambrose on Q2 2018 Results - Earnings Call Transcript

2018-07-27 seekingalpha
Ladies and gentlemen, thank you for standing by. Welcome to the Data I/O Second Quarter Financial Results Conference. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session and instructions will be given at that time. [Operator Instructions]. And as a reminder, this conference is being recorded.

Data I/O Should Bottom Out Here

2018-04-30 seekingalpha
Shares have gone down as fast as they rose last year, but we think both movements have been exaggerated. (1-1)

Data I/O's (DAIO) CEO Anthony Ambrose on Q1 2018 Results - Earnings Call Transcript

2018-04-27 seekingalpha
Ladies and gentlemen, thank you for standing by. Welcome to the Data I/O First Quarter Financial Results Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session, instructions will be given at that time. [Operator Instructions] As a reminder, this conference is being recorded. (25-0)

CUSIP: 237690102